This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Murphy, A. J. Articles by Sheils, O. Search for Related Content PubMed PubMed Citation Articles by Murphy, A. J. Articles by Sheils, O.

Low-Level TOP2A Amplification in Prostate Cancer Is Associated with HER2 Duplication, Androgen Resistance, and Decreased Survival

¹ Department of Cellular Pathology, Adelaide and Meath Hospital and ² Department of Histopathology, Trinity College, Dublin, Ireland

Requests for reprints: Orla Sheils, Department of Histopathology, Room 1.24, Trinity Centre for Health Sciences, St. James's Hospital, James's Street, Dublin 8, Ireland. Phone: 353-1-896-3284; Fax: 353-1-896-3285; E-mail: osheils{at}tcd.ie.

HER2 and TOP2A genes, located on 17q, can be coamplified in cancer. Overexpression of both genes has been reported in high-grade, androgen-resistant prostate cancer. Both genes have not been compared in a single prostate cancer study and the frequency of TOP2A amplifications in prostate cancer is unknown. Using tissue microarrays, we did immunohistochemistry and fluorescence in situ hybridization for HER2 and TOP2A in 100 prostate cancers (41 localized and 59 advanced) and 42 cases of benign prostatic hyperplasia (BPH). Amplification was defined as a target/centromere signal ratio of 1.5. HER2 immunohistochemistry was scored from 0 to 3+. Percentage nuclei staining for topoisomerase II (topoII) was recorded; overexpression was defined as 5% cells staining. Eighteen (31%) advanced prostate cancers showed topoII overexpression; 12 (26%) showed TOP2A low-level amplification; 9 (16%) expressed HER2; and 6 (13%) showed HER2 low-level amplification. No high-level amplification of either gene (target/centromere signal ratio of 3.0) was detected. TOP2A coexpression and coamplification were seen in 75% and 66% of HER2-positive cases, respectively. Localized prostate cancer or BPH showed no gene amplification or topoII overexpression. Gene amplification or overexpression correlated with high stage and Gleason score. The presence of TOP2A amplification in advanced cancer was associated with androgen resistance and decreased survival by multivariate analysis. This is the first study to document low-level TOP2A amplification in prostate cancer and an association with reduced survival. TOP2A amplification may occur with or without HER2 duplication and is often associated with topoII expression. Therapies directed against topoII (and HER2) in such patients may improve survival. [Cancer Res 2007;67(6):2893–8]